1. Melatonin inhibits matrix metalloproteinase-9 (MMP-9) activation in the lipopolysaccharide (LPS)-stimulated RAW 264.7 and BV2 cells and a mouse model of meningitis
- Author
-
Yu-Chang Hung, Hung-Yi Chen, Tsung-Ying Chen, Tian Shung Wu, Wei-Sheng Juan, Chih-Hao Tien, Ying-Hsin Chen, E-Jian Lee, and Che-Chao Chang
- Subjects
medicine.medical_specialty ,Lipopolysaccharide ,Chromosomal translocation ,Inflammation ,Biology ,In vitro ,Melatonin ,chemistry.chemical_compound ,Endocrinology ,chemistry ,In vivo ,Internal medicine ,medicine ,Electrophoretic mobility shift assay ,medicine.symptom ,Neuroinflammation ,medicine.drug - Abstract
We explored anti-inflammatory potential of melatonin against the lipopolysaccharide (LPS)-induced inflammation in vivo and in vitro. RAW 264.7 and BV2 cells were stimulated by LPS, followed by the treatment with melatonin or vehicle at various time intervals. In a mouse model of meningitis induced by LPS, melatonin (5 mg/kg) or vehicle was intravenously injected at 30 min postinsult. The activity of matrix metalloproteinase-2 (MMP-2) and metalloproteinase-9 (MMP-9) was determined by gelatin zymography. Nuclear factor-kappa B (NFκB) translocation and binding activity were determined by immunocytochemistry and electrophoretic mobility shift assay (EMSA). Our results showed that either pretreatment or cotreatment with melatonin at 50–500 μm effectively inhibited the LPS-induced proMMP-9 activation in the RAW 264.7 and BV2 cells, respectively (P
- Published
- 2012
- Full Text
- View/download PDF